Outlook Therapeutics, Inc. (OTLK) Institutional Ownership

Ownership Summary

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has 1 institutional investors that have filed 13F reports for the period ending September 2024.

• These investors collectively held 2.4% of Outlook Therapeutics's outstanding shares in September 2024, up from 1.8% in June 2024.
• Their total shares held in OTLK maintained 0.0% quarter over quarter, and separately, investors owning Outlook Therapeutics decreased 98.75% from a year ago.
• During the quarter, 0 of these 1 funds increased positions in OTLK, 0 reduced exposure, and 1 held steady.
• Altogether, these fund groups held 450.0K shares in OTLK by September 2024, with no net change quarter on quarter, and down 33.43Mn shares year over year.
• ARMISTICE CAPITAL, LLC holds the largest position in OTLK at 4.17Mn shares as of September 30, 2024, or 22.47% of shares outstanding.
• The most significant purchases of OTLK for the quarter ending September 2024 came from ARMISTICE CAPITAL, LLC (4.17Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.97Mn), COMMONWEALTH EQUITY SERVICES, LLC (357.5K), GEODE CAPITAL MANAGEMENT, LLC (287.14K), Warberg Asset Management LLC (275.0K).
• The largest sellers of Outlook Therapeutics for the quarter ending September 2024 were Goldman Sachs Group Inc (81.29K), UBS Group AG (76.47K), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (68.27K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (37.94K), Morgan Stanley (2.22K).
• According to Business Quant data, leading holders of OTLK for September 2024 are ARMISTICE CAPITAL, LLC (4.17Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.97Mn), GEODE CAPITAL MANAGEMENT, LLC (603.61K), GILPIN WEALTH MANAGEMENT, LLC (600.16K), BlackRock, Inc. (477.47K), COMMONWEALTH EQUITY SERVICES, LLC (470.0K), Warberg Asset Management LLC (275.0K), RENAISSANCE TECHNOLOGIES LLC (255.16K), NINE MASTS CAPITAL Ltd (232.55K), Connective Capital Management, LLC (200.0K).